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Tegument proteinincorporating an antigenic repertoire capable of eliciting a cellular immune
response has yet to be successfully implemented for patients who already have acquired an infection. To
address this problem, we have developed a vaccine candidate derived from modiﬁed vaccinia Ankara (MVA)
that expresses three immunodominant antigens (pp65, IE1, IE2) from CMV. The novelty of this vaccine is the
fusion of two adjacent exons from the immediate-early region of CMV, their successful expression inMVA, and
robust immunogenicity in both primary and memory response models. Evaluation of the immunogenicity
of the viral vaccine in mouse models shows that it can stimulate primary immunity against all three antigens
in both the CD4+ and CD8+ T cell subsets. Evaluation of human PBMC from healthy CMV-positive donors
or patients within 6 months of receiving hematopoietic cell transplant shows robust stimulation of existing
CMV-speciﬁc CD4+ and CD8+ T cell subsets.
© 2008 Elsevier Inc. All rights reserved.IntroductionCMV infection is an important complication of transplantation pro-
cedures and affects awide variety of individuals including newborns and
HIV patientswith advanced disease (Pass et al., 2006; Sinclair et al., 2006;
Zaia, 2002). Since the earliest work in the ﬁeld of CMV infection, it has
been a goal to develop a vaccine strategy that would protect at-risk
individuals. The goal of developing effective therapeutics to prevent or to
control CMV infection have been understood in recent years to likely
involve separate classes of host response targets (Khanna and Diamond,
2006). Individuals who are previously CMV-infected or receiving a CMV-
infected solid organ or stem cell allograft are candidates for a vaccine
strategy that targets the cellular reservoir of the virus (Zaia et al., 2001). In
this regard, several antigenshave been identiﬁed as being associatedwith
protective immunity in transplant recipients. These include the tegument
protein pp65 (UL83) and the immediate-early 1 (IE1 or UL123) globalch, Fox South, 1000B, Beckman
Road, Duarte CA 91010, USA.
l rights reserved.gene expression regulator (Boeckh et al., 2006; Cobbold et al., 2005;
Cwynarski et al., 2001; Einsele et al., 2002; Gratama et al., 2001). In
addition, a recentproteomic studyof thewholeCMVgenomedivided into
overlapping peptides showed that pp65 stimulated substantial levels of
both CD8+ and CD4+ Tcells, while IE1mainly stimulated CD8+ Tcells, and
the related IE regulator referred to as IE2 (UL122) stimulated a vigorous
CD8+ and a smaller CD4+ Tcell memory response by a large percentage of
asymptomatic CMV-positive adults (Sylwester et al., 2005). While other
antigens are also recognized with robust cellular immune responses, the
evidence for these three antigens to be highly recognized in amajority of
CMV-infected healthy subjects and transplant patients {this manuscript
and Gallez-Hawkins et al., 2005} is compelling and justiﬁes their
inclusion into a vaccine to prevent viremia and control infection.
Evidence from studies ofmurine CMV (MCMV)point to the important
role of IE1 antigens for development of protective immunity in trans-
plantationmodels (Reddehase et al.,1987).More recently, homologues of
the human CMV pp65 antigen assembled into viral or plasmid DNA
vectors showed evidence of stimulating protective immunity against
MCMV, GPCMV, or RhCMV (Morello et al., 2000; Schleiss et al., 2007; Yue
et al., 2007). Our laboratory has developed modiﬁed vaccinia Ankara
(MVA) into a vaccine for delivering CMV antigens to clinically evaluate
which of them exhibit protective qualities in the context of CMV
Fig. 1. Construction of IEfusion-pZWIIA and pp65–IEfusion-pZWIIA. A) The genomic structure of the regulatory immediate-early genes IE1 and IE2 of HCMV. IE1 is composed of 4
exons (exon1, 2, 3 and 4) indicated by solid dark lines and three introns as indicated by intervening thin lines; IE2 is also composed of 4 exons (exon1, 2, 3 and 5) as indicated by solid
dark lines and three introns as indicated by intervening thin lines. B) Construction of IEfusion gene. Primers a, b, c, d, e are described in Materials and methods. IE1/e4 was ampliﬁed
from the IE1 gene using primers a and b, and was further extended using primer a and c to introduce an internal Apa I site, and external Pme I and Asc I sites. IE2/e5 was ampliﬁed
from the IE2 gene using primers d and e. It was digested at the newly created Apa I and synthetic Asc I site. IE1/e4 and IE2/e5 were joined together by ligation preserving the reading
frame. C) Schematic map of IEfusion-pZWIIA and pp65–IEfusion-pZWIIA MVA transfer plasmids. pZWIIA, an ampicillin resistant plasmid (amp shown in light grey) inserts DNA
sequence within the boundaries of MVA Deletion II via Flanking regions 1 and 2 shown in red (FL1, FL2). pZWIIA has two vaccinia synthetic E/L promoters (green) of slightly different
sequence, arranged head to head to each drive expression of separate genes. IEfusion gene shown in yellow expression is driven by Psyn I promoter (Chakrabarti et al., 1997) and pp65
gene shown in yellow expression is driven by Psyn II promoter (Wyatt et al., 2004). gus bacterial marker gene shown in blue used for identifying recombinant MVA is ﬂanked by two
direct repeat (DR) sequences shown in dark grey to facilitate gus gene removal by intragenomic recombination from IEfusion-MVA or pp65–IEfusion-MVA. In neither transfer
plasmid was pp65 fused to the IEfusion gene. D) Generation of IEfusion-MVA and pp65–IEfusion-MVA. IEfusion-pZWIIA or pp65–IEfusion-pZWIIA was transfected into wtMVA-
infected CEF cells to generate IEfusion-MVA or pp65–IEfusion-MVA via homologous recombination at Deletion II whose ﬂanking region is contained in the plasmid that is
homologous to wtMVA.
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Fig. 2.Western blot (WB) detection of pp65 and IEfusion protein antigens. A) Lane 1: CEF
cell lysate infected with pp65-rMVA as (+) control; Lanes 2 and 3: cell lysate from
wtMVA-infected and uninfected CEF as (−) controls; Lane 4: cell lysate of pp65–IEfusion-
MVA-infected CEF cells. The WB in Panel A was incubated with mAb 28–103 against
pp65. B) Lane 5: cell lysate of CEF infected with rMVA expressing IE1/e4 as (+) control;
Lanes 6 and 7: cell lysate fromwtMVA-infected and uninfected CEF as (−) controls; Lane
8: cell lysate of pp65–IEfusion-MVA-infected CEF cells and Lane 9: cell lysate of IEfusion-
MVA-infected CEF cells. TheWB in Panel B was incubated with mAb p63–27 against IE1.
See Materials and methods for details of MVA construction that clariﬁes that pp65 and
IEfusion are separate proteins of 65 and 125 kDa, respectively.
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Wang et al., 2004b,a, 2007). MVA has an extensive history of successful
delivery into rodents, Rhesusmacaques, and other non-humanprimates,
and more recently as a clinical vaccine in cancer patients (Gilbert et al.,
2006; Peters et al., 2007; Rochlitz et al., 2003). Although MVA is able to
efﬁciently replicate DNA inmammalian cells, it is avirulent because of the
loss of two important host-range genes among N25 mutations and
deletions that occurred during its repeated serial passage in chicken cells
(Antoine et al.,1998;Meyer et al.,1991). In contrast toNYVAC (attenuated
Copenhagen strain) andALVAC (host-range restricted Avipox), both early
and late transcription are unimpaired making MVA a stronger vaccine
candidate (Blanchard et al., 1998; Carroll et al., 1997; Carroll and Moss,
1997; Zhang et al., 2007). Studies in rodents and macaques afﬁrm the
safety of MVA, including protection against more virulent forms of pox
viruses and challenge models and lack of persistence three months
beyond initial dosing administration (de Waal et al., 2004; Earl et al.,
2007; Hanke et al., 2005). Similarly, a therapeutic vaccinationwith MVA
expressing HIV-nef demonstrated its safety in HIV-infected individuals
(Cosma et al., 2003). Finally, MVA immunizations of malaria patients
coinfected with HIV and/or TB conﬁrm the safety of the vector and its
ability to partially protect against a heterologous malaria strain (Gilbert
et al., 2006; Moorthy et al., 2003). These properties form the basis for
our exploration of MVA as a vaccine vector for CMV antigens in
individuals who are severely immunosuppressed andwho are experien-
cing additional complications such asmalignancy or organ failure, there-
by requiring a transplant for which CMV infection is an important
infectious complication.
Our previous work in CMV vaccine development pointed to robust
immunity in mouse models using an MVA expressing pp65 and
IE1exon4 (Wang et al., 2007). We reasoned that development of an IE
fusion protein incorporating the adjacent exon5 would increase the
coverage of additional HLA types by the vaccine, because of the
different HLA recognition proﬁles for both IE1 and IE2 genes. Profound
sequence differences between the major exons of both IE1 and IE2
genes result in a substantial difference in epitope motifs represented
in both genes that is manifested by distinctly different immunologic
proﬁle of recognition among individuals who recognize either gene
product (see Discussion). Both the IE1 and pp65 antigens have been
made into fusion proteins and evaluated as vaccines in primary
immunity models as well as stimulators of memory response using
human peripheral blood from CMV-seropositive individuals (Rohrlich
et al., 2004; Vaz-Santiago et al., 2002). Our approachwas to fuse exon4
from IE1 with exon5 from the IE2 gene into a single gene without
additional genetic material. The fusion protein comprises a more com-
plete representation of the immediate-early antigens than either pro-
tein alone. Our data conﬁrmed the feasibility of fusing both antigens,
since we detected robust immunogenicity in mouse models as well
as studies in human PBMC. Our analysis of this MVA vaccine is based
on measuring CMV-speciﬁc IFN-γ+ T cell responses, which previous
studies from our laboratory and others have shown to be correlated
with cytotoxic function in mouse models and protective immunity in
clinical situations (Avetisyan et al., 2007; Sinclair et al., 2006). The
extraordinary immunogenicity of the recombinant MVA expressing
pp65 and IEfusion antigens provides a strategic approach for deve-
loping a CMV vaccine for transplant recipients.
Results
Construction of the IE1/e4–IE2/e5 fusion (IEfusion) gene, cloning into
transfer vector pZWIIA, and generation of recombinant MVA
IE1, also known as UL123 is composed of four adjacent exons
interspersed with 3 introns while the adjacent UL122 (IE2) gene is
composed of the same initial 3 exons of the UL123 gene but as a result of
alternate splicing, it also contains a unique adjacent exon5 (Fig. 1A)
(White et al., 2007). To approximate the genetic architecture in the CMVgenome and to reduce the number of independent transcription units to
be inserted intoMVA, exon4 (e4) from IE1 and exon5 (e5) from IE2were
joined as shown in Fig. 1B. Genomic copies of e4 and e5 were ampliﬁed
from CMV strain AD169 viral DNA, and primers were developed that
madeuseof a newly created restriction site in IE2/e5 thatwas introduced
into the IE1/e4 fragment by PCR methods. The independent exons with
overlapping sequence were joined at the newly created Apa I site to
create the fusiongenewithout introductionof newprotein sequence.We
omitted exons 2–3, because they contain transcriptional activation
domainswhose activity might cause unexpected gene activation events,
and the omission of a relatively short 85 AA segment seems a reasonable
compromise with safety (Gyulai et al., 2000; Johnson et al., 1999).
The fusion gene was cloned into pZWIIA using unique restriction
enzymes that were added by PCR to the ends of each exon (Fig. 1C).
Versions of the transfer plasmid pZWIIA with UL83 (pp65) were also
constructed (Fig. 1C). pZWIIA encodes two direct repeats ﬂanking the
bacterial marker gene (β-glucoronidase or gus) that facilitates their
removal through stochastic recombination as earlier described (Wang
et al., 2004a). Both versions of pZWIIAwere used in combinationwith
wtMVA to generate rMVA expressing the IEfusion gene alone or co-
expressed with pp65 (Fig. 1D). Since others have created pp65–IE1
fusion proteins, we did not recapitulate those studies and always kept
the pp65 gene separate from the IEfusion gene in the MVA shown in
Fig. 1D. Each rMVA underwent ≥8 rounds of puriﬁcation, and was
veriﬁed to be absent of parental wtMVA using PCR methods (data not
shown) (Wang et al., 2007).
Evaluation of expression of recombinant antigens using Western blot
approach
We tested whether the artiﬁcial joint between IE1/e4 and IE2/e5
would allow continuous translation of the predicted full length pro-
tein product, by infecting CEF with wtMVA and simultaneous trans-
fection with pZWIIA containing the IEfusion gene. The results show
a 125 kDa protein band composed solely of the IE1/e4 and IE2/e5
exons, detected using the IE1/e4-speciﬁc mAb that also detected the
expected 60 kDa band after infection of CEF with IE1/e4-MVA (Wang
et al., 2007) (data not shown). Virus plaques expressing the IEfusion
gene with and without separately co-expressed pp65 were ampliﬁed,
and titered viruses were used to make lysates that were separated
using SDS-PAGE, followed by WB analysis using antibodies to detect
pp65 (Fig. 2A) and IEfusion proteins (Fig. 2B). The results conﬁrm that
Fig. 3. Immunogenicity of pp65–IEfusion-MVA in HHDII mice. A) Percentage of IFN-γ
producing splenocytes speciﬁc for pp65, IE1 and IE2 (x axis) in three mice immunized
with 50 million pfu of pp65–IEfusion-MVA. Grey bars represent pp65-, IE1- and IE2-
speciﬁc IFN-γ production by CD8+ T cells using either peptide epitopes or libraries
(identiﬁed below the x axis) during IVS and ICC stimulations. Unﬁlled bars represent
simultaneous pp65-, IE1- and IE2-speciﬁc IFN-γ production by CD4+ T cells, following
IVS and ICC stimulation with the corresponding CMV libraries indicated below each set
of bars. IVS and ICC stimulation conditions are described in Materials and methods. In
all graphs, error bars represent standard error of the mean among the immunized mice
(N=3). In all experiments, IFN-γ production to mock stimulated cells was subtracted.
P values indicate statistically signiﬁcant differences measured by T-test.
Fig. 4. T cell responses in B7 mice. Percentage of IFN-γ producing splenocytes assessed
by ﬂowcytometry speciﬁc for pp65 (CTL epitope or library), IE1 and IE2 peptide libraries
(x axis) in three mice immunized with 50 million pfu of pp65–IEfusion-MVA, using
methods as described in the legend to Fig. 3. In all graphs, error bars represent standard
error of the mean among the immunized mice (N=3). In all experiments, IFN-γ
production to mock stimulated cells was subtracted. P values indicate statistically
signiﬁcant differences measured by T-test.
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with pp65 (Fig. 2).
Immunogenicity in transgenic HLA A2 mice
To establish whether rMVAwould elicit primary immunity in a CMV-
naïve host, experiments were performed in transgenic (Tg) mice naïve to
all antigens expressed from the rMVA. HHDII mice which are Tg for the
HLAA2gene and focus presentation on the humanMHCwere immunized
with the IEfusion-MVA or pp65–IEfusion-MVA for three weeks (Pascolo
et al., 1997). Spleens were processed and IVS was set up for a period of
7 days followed by ICC to detect IFN-γ expression (see Materials and
methods for details). To evaluate the HLA A2-restricted CD8+ T cell
response we used the immunodominant HLA A2-restricted pp65 and IE1
CTL epitopes, and the IE2 peptide library, since no HLA A2-restricted IE2
epitopes have been deﬁned (Wang et al., 2004b, 2007). To measure MHC
Class II CD4+ T cell responses, peptide libraries speciﬁc for the pp65, IE1,
and IE2 antigens were used both during the IVS and ICC stimulations. The
results presented in Fig. 3 demonstrate robust immunogenicity of the
rMVAafter infection in theHHDIImouse. Levelsof speciﬁc IFN-γproduced
by CD8+ Tcellswere signiﬁcantly higher than for CD4+ Tcells for all 3 CMV
antigens. In contrast, both a robust CD4+ and CD8+ T cell response was
found for pp65 (Fig. 3). Likewise, there was substantial recognition of
the IE1/e4 portion of the IEfusion protein demonstrated by a potent CD8+
T cell response using the IE1 peptide library (Fig. 3). Finally there was a
good CD8+ Tcell response to the IE2 library, and a lesser response by CD4+
Tcells (Fig. 3).Weveriﬁed that the immunogenicity of the IEfusionprotein
was not dependent on the presence of the pp65 antigen by immunizing
HHDII mice with an MVA that included the IEfusion protein without co-
expression of pp65 (data not shown). TheHHDIImice responded similarly
to the IE2 library, and also appropriately responded to the HLA-A2
restricted epitope of IE1 in a robust manner. These experiments conﬁrm
the strong immunogenicity of the IEfusionprotein, and also verify that the
immunogenicity of the IE1 portion of themolecule is not disrupted when
the IE2 portion is fused to it. The immunogenicity of the IE1 portion
compares favorably to constructs inwhich IE1/e4 is expressed as a single
exonwithout fusion (Wang et al., 2004b, 2007).
Immunization of Tg HLA B7 Kbko/Dbko (B7 mice) with
pp65–IEfusion-MVA
The success of the immunogenicity trial inHHDIImice prompted us
to investigate a Tgmodel expressing a different HLA allele to generalizethe scope of immunogenicity of the rMVA in differentHLA backgrounds.
B7 mice are deﬁcient in both Kb and Db murine genes, and mainly
process Class I antigens using the Tg MHC molecule, HLA B⁎0702
(Rohrlich et al., 2003). Immunization conditions were similar as we
described for HHDII mice, and after threeweeks, mice splenocyteswere
stimulated during both IVS and ICC procedures with HLA B⁎0702
pp65265–275 epitope to evaluate the Tg CD8+ T cell response. Since in B7
mice the recognition of HLA B⁎0702 IE1 epitopes is minimal (unpub-
lished results) we used the IE1 peptide library to measure the Tg CD8+ T
cell response (Fig. 4). Peptide libraries speciﬁc for the pp65, IE1, and IE2
antigens were also used to evaluate the MHC Class II responses. Similar
to the ﬁndings in HHDII mice, higher levels of CD8+ and lower levels of
CD4+ T cell responses were elicited against all 3 CMV antigens (Fig. 4).
This evaluation demonstrates that both the pp65 and IEfusion genes are
functional and immunologically recognized in the Tg HLA B7 mouse
model.
Ex vivo response to CMV-pp65, IE1, and IE2 peptide libraries in healthy
volunteers and HCT recipients
To best gauge the strength of the rMVA to stimulate CMV-speciﬁc T
cells from PBMC of CMV positives, we ﬁrst examined the ex vivo
recognition of the three peptide libraries (pp65, IE1, IE2) corresponding
to the cognate expressed proteins in rMVA. We conducted measure-
ments on 22 CMV-positive (Fig. 5) and 8 CMV-negative healthy adults
(data not shown). We classiﬁed individuals as responders if they
had antigen-speciﬁc T cell frequencies of greater magnitude than
levels found in CMVnegatives, which averaged 0.05% of CD8+ and 0.08%
of CD4+ T cells for each of the 3 peptide libraries (data not shown). The
number of individuals classiﬁed as responders was highest for pp65 in
both the CD8 (16/22) and CD4 (10/22) subsets, and there were lower
numbers of responders (9/22) for both the IE1 and IE2 library in CD8, but
far fewer (3/22) in theCD4subset. Thenumberof individuals responding
to the 3 peptide libraries is qualitatively similar to the only other
comparable dataset (Sylwester et al., 2005). We then calculated the
CMV-speciﬁc CD8+ and CD4+ T cell frequencies for each of the 22 CMV
positives, and found roughly equivalent response levels to all 3 libraries
in the CD8+ T cell subset (Fig. 5A). In contrast, there was a dichotomy of
response in the CD4+ T cell subset such that pp65 responses were on
average N3-fold higher than found in IE responders, which agrees with
ﬁndings from previous investigators (Sylwester et al., 2005). In
summary, the T cell responses of this randomly chosen group of CMV
positives is qualitatively in accord with the previous study, conﬁrming
the reliability of our approach and the legitimacy of using results from
our healthy volunteer group as a benchmark for comparisons with less
well characterized HCT patients.
Fig. 5. Ex vivo response to pp65, IE1, and IE2 peptide libraries. A) Responses in healthy volunteers. PBMC were obtained from N=22 healthy volunteers for which we had complete
HLA typing. Five million PBMC were divided into four aliquots and were individually co-incubated with peptide libraries at 1 μg/ml/peptide in single use aliquots as described in
Materials and methods. PBMC from each individual were treated in separate cultures with each peptide library at the same time, but not all individuals were evaluated on the same
day. Standard gating procedures were employed for each individual ﬂow acquisition, such that conditions were standardized for all evaluations. Separate aliquots from the ICC assay
were incubated with CD4+, CD8+ or isotype control antibodies as described in Materials and methods. The plots show the percentage of IFN-γ producing T Cells for each of the
antigen-speciﬁc peptide libraries. Error bars represent the standard error of the mean calculated using Microsoft Excel statistical package. B) Ex vivo response of PBMC from HCT
recipients. Three examples from each of three separate risk categories of HCT shown in 3 separate plots (L-R; D+/R+, D−/R+, D−/R+) based on CMV status were evaluated for response
against peptide libraries using the same technical approach as described in A). Data from all 3 individuals was averaged in each category, and the error bars represent the standard
error of the mean.
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immune response of stem cell transplant (HCT) recipients to all three
peptide libraries in three combinations of donor (D) and recipient (R)
pairs with increasing risk for complications of CMV infection (D+/R+, D+/
R− and D−/R+) at 180 days post-transplant (Fig. 5B). All 9 recipients that
we chose were part of a study of natural development of immunity to
CMV and were known responders to CMV antigens (Gallez-Hawkins
et al., 2005; Lacey et al., 2006). All 9 patients responded to the 3 peptide
libraries by producing a CD8+ T cell response of similar magnitude to
healthyadultswith chronic CMV infection (Fig. 5A). Similar to the results
for healthy volunteers, the pp65 library stimulated a strong response in
both theCD4+ andCD8+ Tcell subset,while the IE1 and IE2 librarieswere
most effective for stimulating a CD8+ T cell response (Fig. 5B). The low
level of CD4+ T cell response to both the IE1 and IE2 libraries is also
consistent with previous reports and our results in healthy volunteers.
These observations indicate that both the magnitude and quality of the
T cell response to the pp65, IE1, and IE2 antigens are similar in recover-
ing HCT recipients as it is in healthy CMV-positive volunteers.
IEfusion-MVA stimulates CMV-speciﬁc T cells in human PBMC
We examined the immunogenicity of the IEfusion protein as a single
immunogen or co-expressed with pp65 in rMVA. Autologous APC arematured to be optimally receptive to MVA infection and antigen
presentation by the use of a CpG DNA cocktail (La Rosa et al., 2006).
Following three days of maturation, APC are infected with rMVA
containing the IEfusion gene or rMVA containing both the IEfusion and
pp65 genes, followed by irradiation to inactivate the APC for prolifera-
tion. We examined IEfusion-MVA in PBMC from three CMV-positive
healthy donors and one CMV-negative donor. ex vivo recognition of
either the IE1 or IE2 peptide libraries was ﬁrst conducted as a com-
parison to the MVA IVS study (Fig. 6A). The average increase was quite
substantial after IVS with IEfusion-MVA, nearing 5-fold in each of the
three CMV-positive individuals evaluated in either the CD4+ or CD8+
subset as detected with the IE1 or IE2 peptide libraries (Fig. 6A). In
contrast, there was no evidence for ex vivo recognition of peptide lib-
raries in the CMV-negative individual, nor was there any signiﬁcant
stimulation of either IE-speciﬁc T cell population (data not shown). As
expected, no evidence of pp65-speciﬁc stimulation beyond ex vivo levels
was found in both CMV positives and negatives, because the rMVA did
not express pp65.
The immunogenicity of pp65–IEfusion-MVA was assessed by
comparison to ex vivo measurements of the autologous PBMC popula-
tions using all three peptide libraries (Fig. 6B). In all individuals exa-
mined, therewas brisk stimulation of antigen-speciﬁc Tcell populations
that often exceeded levels foundwith IEfusion-MVA (Fig. 6A). In the case
Fig. 6. rMVA stimulates CMV-speciﬁc T cells in human PBMC. A) Using the IEfusion-MVA, as described in Materials andmethods, APC were infected for 5–6 h, irradiated, and then co-
incubated with unmanipulated PBMC from the autologous individual. The time course and conditions of the IVS are described in Materials and methods. Four separate evaluations
were conducted with each IVS culture as shown in Panel A. After treatment with the peptide library, and ICC was performed, and aliquots of PBMC were either stained with CD4 or
CD8 antibodies as described in Fig. 5A. Results shown are averages of measurements from three CMV-positive individuals selected randomly from our cohort of blood donors. Not
shown is a comparison with a CMV-negative donor who showed no speciﬁc recognition of any of the three peptide libraries after IVS with IEfusion- and pp65–IEfusion-MVA.
B) Similar to A), but using the pp65–IEfusion-MVA, IVS was carried out using conditions identical as in A) and fully described in Materials and methods. PBMC from 8 healthy CMV-
positive blood donors were evaluated both ex vivowithout manipulation and post-IVS following infection with rMVA as described in A). Statistical differences between ex vivo levels
of CMV-speciﬁc T Cells versus post-IVS were calculated as described in Materials and methods, and when a P value is ≤0.05, it is shown above the error bar for each evaluation of
individual peptide libraries. All methods for IVS, ICC, and ﬂow cytometry are described in Materials and methods.
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antigen-speciﬁc T cell populations. As expected, the ex vivo level of the
CD4+ subset recognizing pp65 was far greater than for the IE antigens,
which was also reﬂected in the ampliﬁed frequencies after IVS with
rMVA.Using the sameCMV-negativehealthydonor thatwe investigated
with IEfusion-MVA, we found no evidence of pp65 or IEfusion-speciﬁc
immunity after in vitro immunization with pp65–IEfusion-MVA (data
not shown). Results from both vaccine viruses establish that rMVA
stimulation does not substantially alter the relationship of the T cell
subset proportionmeasured ex vivo for all three antigens; it ampliﬁes ex
vivo levels to a higher level after IVS (Figs. 6A and B). As a further control
for speciﬁcity of CMV antigen recognition, we investigated in vitro
immunization of PBMC from 3 healthy donors shown in Fig. 6B with an
MVA only expressing the Gus gene (Gus-MVA) that was constructed
usingdifferent transfer vectors anddescribed in aprevious report (Wang
et al., 2004a). As expected, there was no incremental increase in CMV-speciﬁc recognition of all 3 peptide libraries greater than what was
measured ex vivo (data not shown).
rMVA stimulates CMV-speciﬁc effectors in PBMC from transplant
recipients
The success of the studies in healthy adults prompted us to evaluate
the capability of the three-antigen rMVA to stimulate memory res-
ponses in PBMC from HCT recipients. In our evaluation, two examples
were chosen from three different risk categories of patients that were
also examined ex vivo: D+/R+, D−/R+ and D+/R− (Fig. 5B). Results of the
IVS with MVA are shown juxtaposed to the ex vivo response to
demonstrate the magnitude of the stimulation of CMV-speciﬁc T cell
responses in all patient risk groups (Fig. 7). The CD8+ was more sub-
stantial than the CD4+ T cell stimulation which reﬂected the ex vivo
proﬁle, which shows substantial over-representation of CD8 versus
Fig. 7. rMVA stimulates CMV-speciﬁc T cells in PBMC from HCT recipients. Six examples of patients that were evaluated for response to peptide libraries shown in Fig. 5B were also
evaluated after IVS with pp65–IEfusion-MVA. Methods including conditions for IVS, post-IVS analysis of cell population, ICC, and ﬂow cytometry are identical as described in Fig. 6. A
comparisonwas made between the ex vivo level versus post-IVS for each stimulation, and each category of donor and recipient serostatus is shown in 3 separate plots as discussed in
the legend to Fig. 5B.
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speciﬁc T cells in many cases exceed those found in healthy volunteers
(Figs. 6 and 7). This is evident in both the CD4 and CD8 T cell po-
pulations, and is observed in all three patient groups with different
combinations of CMV serostatus. While not all antigens were equally
stimulated in all patients, themajority ofmeasurements demonstrate a
substantial ampliﬁcation from ex vivo levels in both the CD4+ and CD8+
T cell population. The speciﬁcity of the immune responses to CMV
antigens was conﬁrmed by including an additional in vitro immuniza-
tion culture using Gus-MVA, from two of the six HCT patients that we
were fortunate to have sufﬁcient PMBC to conduct this additional
control (data not shown). There was no evidence of CMV-speciﬁc
immune stimulation, beyond what was measured ex vivo from both
individuals (Fig. 7 and data not shown).
Discussion
The goal of deriving pp65–IEfusion-MVA is to expand the diversity of
cellular immune responses against CMV to counter viremia in the
immunosuppressed patient. The rationale of this vaccine virus is to
include antigens from CMV that are expressed early to disrupt the viral
life cycle. In contrast to previous efforts, we sought to maximize the
representation of IE-speciﬁc immunity by including both the IE1 and IE2
antigens. pp65, IE1, followed by IE2, rank among the best recognized
antigens in the CD8 subset, and with the largest proportion of the T cell
memory response to CMV (Sylwester et al., 2005). Interestingly, there is
no region of homology greater than 5 amino acids between the major
exons of both proteins. Individually, both antigens are recognized
broadly by almost 70% of the general population (Sylwester et al., 2005).
While few epitopes have been mapped to unique sequence positions of
either gene, the divergent sequence of both IE1/e4 and IE2/e5 used inour construction predicts an entirely different subset of HLA binding
peptides using publicly available Class I and II motif algorithms (Peters
and Sette, 2007). Human subjects that we empirically evaluated for
recognition of both IE1 and IE2 antigenswere found inmany instances to
recognizeone or the other but not both. Among the research subjectswe
analyzed, 24% recognized IE2 with or without pp65 to the exclusion of
IE1 (data not shown). This result strongly suggests that the recognition
elements for both antigens are unique, and by including both of them in
the vaccine, we extend the breadth of individuals with disparate HLA
types that will recognize and develop an immune response to the
vaccine.We potentially double the level of recognition of IE genes based
on our own results and what was previously reported (Sylwester et al.,
2005). The fusion of major exons from both antigens achieves the twin
goal of reducing thenumberof separate inserts andeliminating theneed
for a third insert promoter. The advantages of this approach include
placementof all vaccineantigens in onevector, anddiminishing thedose
of virus needed to attain sufﬁcient immunity simultaneously against all
of the included antigens.
The IEfusion gene has not been previously evaluated as an im-
munogen. We conducted extensive analysis to establish parameters of
expression and immunogenicity to qualify it for potential clinical use.
Two forms of rMVAwere designed to test the IEfusionprotein, either as
a single antigen or combined with pp65. This dual evaluation allowed
conclusions about the capacity of various immunologic tests to accu-
rately score the antigen as being recognized as a single entity or in
combinationwith another strongly immunogenic antigen.We demon-
strated strong expression of the IEfusion protein as a single-antigen
MVA or in combination with pp65. In either virus, the antigen was
stronglyexpressed behind the synthetic E/L promoter (Psyn I). This test
demonstrates that the presence of pp65 did not interferewith IEfusion
protein expression, since there were earlier reports of interference
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is immunologically recognized, either alone or in combination with the
pp65 antigen. Equally important to the success of the MVA vaccine is the
reduced levels of inﬂammation it stimulates allowing for repeated
boosting, and the role of pre-existing immunity to the vector, perhaps
caused by an earlier smallpox vaccination using theDryvax™ vaccine. Our
work and the work of others suggest that limited repeated exposures to
MVA inadeﬁnedvaccineperiodofmonths canbe tolerated (Ramirezet al.,
2000; Wang et al., 2004a; Yang et al., 2003). Hammerlund et al. com-
mented on the longevity of poxvirus-speciﬁc Tcell response decades after
Dryvax™ immunization, and point out that cellular immunity decays
more rapidly than humoral immunity (Hammarlund et al., 2003). The
ability to re-stimulate pox-speciﬁc memory responses is dictated by the
length of time since the last exposure to the virus.
Humanized Tg mice which do not express murine Class I alleles
(Lemonnier, 2002) are available in a variety of forms that express
human HLA A2, B7, A11, providing the most direct way to assess HLA
recognition of vaccines in a mouse model (Firat et al., 2002). We ﬁrst
examined the processing of both rMVAs utilizing HHD II mice, which
are known to be effective in processing and recognition of poxviruses
speciﬁc for a wide variety of infectious pathogens, including CMV
(Daftarian et al., 2003; Gomez et al., 2007; Wang et al., 2004b). Our
results substantiate that the IEfusion antigen in MVA is processed and
immunologically recognized throughout both exons, and the fusion
join does not impede this process. A limitation of this study was the
exclusive use of IFN-γ to assess T cell recognition of CMV antigens
expressed fromthe vaccine, thoughwe andothers have showna strong
correlation between IFN-γ expression and cytotoxic function inmouse
models (Daftarian et al., 2003; Song et al., 2007;Wang et al., 2004a). In
addition, measurement of IFN-γ production has been relied upon to
assess CMV immunity in CMV-infected healthy individuals (Ghanekar
et al., 2001; Sinclair et al., 2004; Sylwester et al., 2005).
To further generalize the capacity of the rMVA vaccine to be
recognized in a variety of HLA context, B7 mice with a similar C57BL/6
background as the HHDII mice were also immunized with the pp65–
IEfusion-MVA and investigated for immunogenicity using the same
approach as with the HHDII mice. As expected, we found highly
effective recognition of the pp65 antigen as well as a CD8 response to
the IE2 antigen using the peptide library. This series of experiments
illustrates that rMVA is processed efﬁciently by multiple HLA alleles,
and provides further support for its utility as a clinical vaccine strategy.
WhileHLAClass I Tgmice serve a fundamental and irreplaceable role to
demonstrate the immunogenicity of the MVA constructs; however,
they cannot be directly compared with the human in vitro clinical
results, since the latter were obtained exclusively using CMV-speciﬁc
peptide libraries. Humans express a diversity of HLA alleles, and the
purpose for developing a multi-antigen vaccine is to encompass as
many as possible to broaden the applicability of the vaccine to outbred
human populations. While the Tg mice are a valuable tool to evaluate
HLA Class I restricted CD8 T cell responses, they have an intact full
complement of murine MHC Class II genes and cannot be directly
compared to humans who possess a different repertoire of Class II
MHC. While not an optimal comparison, it is noteworthy that of the
three antigens, pp65 elicits the strongest CD4 response in both mice
and humans. In contrast both IE1 and IE2 do not elicit strong CD4-
based immunity in both mice and humans (compare Figs. 3 and 5).
Prior to conducting experiments with rMVA in clinical samples, we
assessed the capacity for stimulation of both CD4+ and CD8+ Tcells using
the commercially available pp65 and IE1 library and our newly designed
IE2 peptide library.We found relationships among the Tcell populations
to be similar towhat has beenpublished, as pp65 promotes a substantial
CD4 and CD8 response in over 70% of participants, while IE1 and IE2 are
recognized less frequently and mainly in the CD8+ T cell compartment
(Khan et al., 2002, 2007; Sylwester et al., 2005). The conclusion from the
library studies suggest that our IE2 formulation is a reagent of equal
potency to the commercially available pp65 and IE1 peptide libraries toassess memory T cell responses in the volunteer pool, and should be an
effective detection reagent of memory immune responses to rMVA. We
also evaluated recognition of all three libraries in transplant recipients in
all three risk groups including those with CMV-positive or -negative
donors or themselves being CMV-negative with a CMV-positive donor.
The uniqueness of this study is that no previous evaluation of peptide
libraries has been carried out with HCT recipients using all three anti-
gens simultaneously (Lacey et al., 2006). We examined patient samples
at day 180 post-transplant to minimize the effects of myeloablation and
incomplete immune reconstitution on the recognition of the peptide
libraries. The immune recognition of all three libraries was successful
in all patients, and interestingly, the relative proportion of T cells that
responded to each library also mirrored what was found in the healthy
volunteers.
We evaluated both rMVA expressing the IEfusion antigen in PBMC
fromhealthy volunteers to establish their recognition properties using a
fully human system. The results showed that the memory T cell
expansion stimulated by the rMVA for both the IEfusion and pp65
antigens, followed theproportions found ex vivo for the same volunteers
using the peptide library approach. While there was substantial
ampliﬁcation of the relevant T cell populations, the stimulation did not
skew the population towards a particular subset or antigen speciﬁcity.
The data also conﬁrms that the IEfusion protein is processed and
presented appropriately to stimulate existing T cell populations in a
manner thatmaintains the phenotypic distribution as expected in the ex
vivo analysis. This outcome ismost favorable towards using the rMVA as
a vaccine in both CMV positives and negatives, since it is preferable to
maintain the proportion of T cells that are associated with an
asymptomatic phenotype and hopefully induce that same proportion
in CMV-negative subjects. In this report, we succeeded in stimulating
primary immunity in CMV-naïve mice using in vivo immunization, but
failed to elicit primary responses from clinical samples in the CMV-naïve
subject we investigated. The conditions of in vitro immunization are
insufﬁcient in most cases to drive primary immunity, because the
architecture of the lymph node, thymus and dendritic cell systems is
missing, so the T cell precursors must pre-exist or form in culture.
Developing primary immunity to CMV post-transplant is often delayed
in the CMV-naïve recipient or donor in the case of stem cell transplant,
and is thought to be a risk factor for CMV disease (Limaye et al., 2006;
Ljungman et al., 2006). Precedent for poxvirus-based CMV vaccines to
stimulate primary immunity was established with a single-antigen
pp65-ALVAC used in a clinical trial conducted with CMV-negative
healthy volunteers (Berencsi et al., 2001).
The inability to rely on in vitro immunization for eliciting primary
immunity is a keymotivation inpursuing avaccine, since the pioneering
approaches of adoptive transferwould be infeasiblewhen considering a
CMV-negative donor for HCT, or a CMV-negative recipient of a CMV-
infecteddonororgan (Walter et al.,1995). Recently, our grouphas shown
that MVA vaccines composed of CMV subunit antigens (e.g. pp65, IE1,
and gB) can elicit primary immunity in CMV-naïve rhesus macaques,
even offering partial protection against a challenge dose of rhesus CMV
(Yue et al., 2008). Consequently, since rMVA or ALVAC expressing CMV
antigens predictably expand Tcell populations in both CMV-naïve (mice
and macaques) and experienced (human) hosts, one application of a
CMV vaccine is in the high-risk CMV-negative transplant recipient for
protection against the effects of a CMV-infected organ. One scenario
would be to introduce the pp65–IEfusion-MVA as a vaccine into the
CMV-negative recipient as a precaution several months before trans-
plant (Khanna and Diamond, 2006; La Rosa et al., 2007). Another
application is to use pp65–IEfusion-MVA as a vehicle to expand T cell
populations from CMV-positive donors of HCT, and infuse the ampliﬁed
T cells into a transplant recipient with active viremia. The proof of
principle for that application has been demonstrated in HCT using
different approaches, though the level of ampliﬁcation and short time
frame provided by rMVA makes it an attractive candidate for this
application (Cobbold et al., 2005; Einsele et al., 2002;Walter et al.,1995).
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racterizing memory responses. The concurrent activating and immu-
nosuppressive properties of CMV can confound interpretation of
immunologic methods using it for in vitro stimulation (Manley et al.,
2004). In fact, one needs to artiﬁcially remove the immune-evasion
genes from CMV in order to elicit a diverse immune response that
includes the IE antigens, a fact that has been stressed in the literature
(Khan et al., 2005; Manley et al., 2004). Laboratory strains of CMV that
are the only practical approach for growing the virus to assess recall
immunity are plagued with an artiﬁcial excessive accumulation of the
pp65 protein that interferes with the recognition of IE proteins which
also has been discussed in the literature and has been the source of
controversy in the ﬁeld (Gilbert et al., 1996; Kern et al., 1999; Wills
et al., 1996). Therefore, it is to be expected that the proﬁle of immune
responses that are stimulated byMVAwill be different thanwhat could
be elicited using CMV as a viral stimulator in culture methods.
Themost rigorous evaluation of the processing of the rMVA for Tcell
response is using PBMC from transplant patients. Evaluating PBMC
fromHCT recipients in all three risk categories,we found anequivalently
strong recognition of both rMVAs, in some cases more vigorous than
in the PBMC of healthy adults. We found no interference with the
recognition of the IE antigen by the co-expressed pp65 antigen from
the same rMVA, which further conﬁrms that the recognition of both
antigens can take place at the same time and derived from the same
vector. Prime-boost strategies utilizing heterologous vaccines, including
DNA and viral vectors, suggest improved immunogenicity in several
pathogen models, including malaria and HIV (Barouch et al., 2003;
Gilbert et al., 2006; Goonetilleke et al., 2006; Peters et al., 2007). The
ongoingevaluationof aDNAvaccine against CMV suggests aworthwhile
strategy of combining MVA with a plasmid DNA vaccine. The excellent
track record of MVA used as a vaccine in the immunosuppressed
populationmakes it an ideal candidate as a therapeutic inHCTrecipients
(Cosma et al., 2003; Mayr and Danner, 1978; Stittelaar et al., 2001).
Materials and methods
Human patient specimens
The study protocols were approved by the institutional review
board at City of Hope Medical Center (COH), and specimens and data
were obtained prospectively after informed consent was obtained
from subjects. PBMC from healthy donors and 9 HCT recipients at d180
post-transplant were collected at COH and cryopreserved by standard
methods (Maecker et al., 2005). HLA typing was performed at the COH
HLA Laboratory by standard SSOPmethods. Haplotypes for both Class I
and II alleles were determined (data not shown). No intentional bias
occurred in selection of HLA types to be included in this study, as all
patients or volunteers were randomly chosen. The CMV serostatus of
these subjects was determined as previously described by using latex
agglutination (CMV-SCAN; Becton Dickinson) (La Rosa et al., 2007).
Mouse strains and conditions of immunization
HHD II (Pascolo et al., 1997) and HLA B⁎0702 (Rohrlich et al., 2003)
Tg mice were bred and maintained under pathogen-free conditions in
the AALAC-approved animal care facility at COH. Eight to ten-week old
groups of Tg mice (3–4) were immunized i.p. with different rMVA
constructs (as described in the ﬁgure legends).
Synthetic peptides and monoclonal antibodies
HLA-A⁎0201 pp65495–503 (Diamond et al., 1997), HLA B⁎0702
pp65265–275 (Longmate et al., 2001) and HLA-A⁎02 IE1316–324 (Khan
et al., 2002) restricted CMV peptides were used as previously described
(La Rosa et al., 2001). Overlapping 15-AA peptides (PepMix™) spanning
full length CMVpp65 and IE1 proteinswere purchased from JPT PeptideTechnologies GmbH (Berlin, Germany). Splenic murine cell suspensions
were evaluated in ﬂow cytometry using the following antibodies: CD8-
FITC (Clone Ly-2), CD4-PE (Clone L3T4), and IFN-γ-APC (Clone XMG1.2).
Antibodies used for ﬂow cytometry of clinical specimens include anti-
humanCD8-PE (CloneRPA-T8), CD4-FITC (CloneRPA-T4) and IFN-γ-APC
(Clone B27), purchased from BD-Pharmingen.
Construction of synthetic IE2 peptide library
The 580 amino acid primary sequence of the IE2 protein [Swiss Prot
#P19893] was divided into 15mer stretches that overlap successive
peptides by 11 amino acids using an online program which excludes
impermissible amino acids at the amino (Q) and carboxyl (GPEDQNTSC)
terminus of each 15mer peptide based on synthetic considerations. 133
peptides were predicted using the algorithmwith an average length of 15
AA, but tolerating up to 5-AA length variance to eliminate forbidden
terminal amino acids. A total of 123 peptides were synthesized in our
laboratorywith a Symphony™ peptide synthesizer (Protein Technologies,
Inc., Tucson, AZ) using standard 9-ﬂuorenylmethoxy carbonyl protocols
and puriﬁed by high performance liquid chromatography (Agilent
Technologies 1200 series) (Daftarian et al., 2005). The mass of each
peptidewas conﬁrmedbymatrix assisted laser desorption ionization time
of ﬂight analysis using a Kompact Probe™mass spectrometer (Shimadzu
Corp., Chestnut Ridge, NY). The librarywas sub-divided into ~20 peptides/
pool, and subsequently combined into one super-pool containing all the
component peptides. Several peptideswere impractical to synthesize, and
theydidnotenter into thepool includinga32-AAstretchbetween251and
282 of IE2 sequence. All peptides were individually solubilized in 30%
acetonitrile/water, except 6 with pKs N8, which were dissolved in 0.1%
ammonium bicarbonate in 30% acetonitrile/water. The solubilized pep-
tides, sub-divided into six pools, were further combined into a single
super-pool,witheachpeptide at a concentrationof 200 μg/ml, dissolved in
50% DMSO/water, and kept at −80 °C in single use aliquots. The single use
aliquots were diluted into cell culture medium at a ﬁnal concentration of
1 μg/ml/peptide for all cellular immunology assays based on previous
titration studies (data not shown).
Construction of recombination plasmids for derivation of rMVA
TheMVA transfer plasmid namedpZWIIAwith dual vaccinia synthetic
promoters (Psyn I and II) was constructed to facilitate the derivation of
bacterial marker gene-free rMVA (Wang et al., 2007). To construct the
IEfusion gene, the following primers were designed with synthetic res-
triction enzyme sites shown as underlined: Primer a: 5′ AGCTTTGTTTAA-
ACGCCACCA CCATGGTCAAACAGATTAAGGTTCG 3′; Primer b: 5′GGCA-
TGATTGACAGCCTGGG CGAGGATGTCACCCTGGTCAGCCTTGCTTCTAGT-
CACCAT 3′; Primer c: 5′TGTTAG CGTGGGCCCGGTGCTACTGGAATCGATA-
CCGGCATGATTGACAGCCTGGGCGAGG ATGTCACC 3′; Primer d: 5′ TAG-
CACCGGGCCCACGCTAACAACCCAC3′;Primer e: 5′ TTGGCGCGCCTTTATTT-
TACTGAGACTTGTTCCTCAGGT 3′. Primers a and b were used to amplify
IE1/e4, and after gel puriﬁcation, the IE1/e4 PCR product was ampliﬁed
again using Primers a and c and digested with Pme I and Apa I. Primer b
overlaps the junction between IE/e4 and IE2/e5 without adding any non-
CMV genomic sequence. Primers c (G to C) and d (C to G) contain a single
nucleotide change (double underline) that creates an Apa I site, but does
not alter the amino acid sequence. The resulting fragment was cloned
into pNEB193 to yield IE1/e4-pNEB193. IE2/e5 was ampliﬁed using Pri-
mers d and e and PCR products were digested with Apa I and Asc I and
cloned into IE1/e4–pNEB193 to yield IE1–IE2–pNEB193. IE1–IE2 fusion
gene (IEfusion) was excised from IE1–IE2–pNEB193 with Pme I and Asc I
restriction enzymes and cloned into pZWIIA behind vaccinia Psyn I
promoter (Chakrabarti et al., 1997) to yield IEfusion-pZWIIA (Fig. 1C). To
construct pp65–IEfusion-pZWIIA, the 1.7 kb CMV pp65 gene was PCR
ampliﬁed from an existing plasmid and cloned into Nhe I and Asc I sites of
pZWIIA behind vaccinia Psyn II promoter (Wyatt et al., 2004) to yield
pp65–IEfusion-pZWIIA (Fig. 1C). In neither MVA was pp65 fused to the
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digestion and DNA sequencing.
Generation of IEfusion-MVA and pp65–IEfusion-MVA
pp65–IEfusion-MVA was generated in CEF cells via homologous
recombinationby transfection/infectionmethodasdescribedpreviously
(Wang et al., 2004a, 2007). pp65–IEfusion-MVA was isolated based on
blue color selection bynine consecutive roundsof plaquepuriﬁcation on
CEF cells in the presence ofβ-glucoronidase substrate (X-glcA). IEfusion-
MVAwas generated similarly to pp65–IEfusion-MVA. The gus selection
marker gene in rMVA virus was screened out using a limiting dilution
method as described previously (Wang et al., 2007). Wt MVA-free and
color marker gene-free recombinant IEfusion-MVA and pp65–IEfusion-
MVA virus were expanded and puriﬁed by 36% sucrose density
ultracentrifugation, resuspended in PBS containing 7.5% lactose, re-
tested forproteinexpressionbywesternblot (WB), aliquoted, and frozen
at −80 °C.
Western blot detection of protein expression
The pp65 and IEfusion protein expression levels, measured as
separate proteins with distinct molecular weights from IEfusion-MVA
and pp65–IEfusion-MVA-infected cells was determined by WB using
an enhanced chemiluminescence-based ECL Plus™ detection kit
(Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
After electro-transfer of proteins from the gel onto PVDF membranes
(Bio-Rad, Hercules, CA), the membranes were incubated ﬁrst with
puriﬁed mAb 28–103 (Britt and Auger, 1985) to detect pp65 as a
separate protein, or mAb p63–27 (Plachter et al., 1993) to detect the
IE1 or IEfusion protein, followedwith HRP-labeled goat anti-mouse Ab
according to the manufacturer's instructions.
Ex vivo and in vitro stimulation conditions for human PBMC
Cryopreserved PBMC were rapidly thawed and immediately cul-
tured in 15-ml Falcon tubes at a density of 1 million/ml in RPMI 1640
medium (Invitrogen) supplemented with 10% FCS (Omega Scientiﬁc
Inc, Tarzana, CA) and containing either pp65 PepMix™, IE1 PepMix™
or IE2 peptide library (at a ﬁnal concentration of 1 μg/ml of the
individual peptides) at 37 °C in a 5% CO2-gassed incubator. After 1 h in
culture, brefeldin A (GolgiPlug; Becton Dickinson Biosciences) was
added, and incubation continued for an additional 11 h under the same
conditions. IVS using rMVAwasmodiﬁed from a publishedmethod (La
Rosa et al., 2006). Brieﬂy, cryopreserved PBMCs were rapidly thawed
and immediately dispensed in a 12-well plate at a concentration of
2×106 cells/ml in RPMI 1640 medium (2.5 ml/well) supplemented
with 10% human AB serum (COHBlood Bank) andwere incubatedwith
5 μg/ml of both CpG-A ODN 2216 and CpG-B ODN 2006 (TriLink
BioTechnologies, SanDiego, CA, USA). After 3 days,ODN-treated PBMCs
were infected with rMVA expressing pp65 and IEfusion antigens
(pp65–IEfusion-MVA), or rMVAexpressing pp65 and IE1 exon4 (pp65–
IE1-MVA), or rMVAexpressingonly IEfusion antigen (IEfusion-MVA) at
a multiplicity of infection of 5, for 6 h in RPMI 1640 medium with
reduced (2%) human AB serum. Infected PBMCs were γ-irradiated
(2500 rad) and used as APC. APC were plated in a 24-well plate
(1.5×106/well), co-incubated with autologous PBMC (3×106/well), in
a ﬁnal volume consisting of 2 ml/well RPMI 1640 medium with 10%
human AB serum and human rIL-2 (NIH AIDS Research and Reference
Reagent Program, 10 units/ml). Every 2 days, 50% of the culture
medium was removed, and replaced with fresh medium containing
rIL2. Cells were incubated for 8 days and split into additional wells
when necessary. At day 8, cells were collected and washed with
medium without rIL-2 and transferred into 15 ml Falcon tubes. The
same stimulation conditions for intracellular cytokine (ICC) assays
performed on ex vivo PBMC were used for PBMC after IVS.Intracellular cytokine staining of human PBMC
After 12 h of incubation, PBMC were harvested, washed, labeled with
PE-conjugated anti-CD8 and FITC-conjugated anti-CD4 antibodies, ﬁxed,
and permeabilized (Cytoﬁx-Cytoperm; Becton Dickinson Biosciences)
before they were labeled with APC-conjugated antibody to IFN-γ. The
stained cells were analyzed on a FACSCanto™ (BD Immunocytometry
Systems, San Jose, CA), and datawere analyzed using FCS Express (version
3.0; DeNovo Software). 0.5×106 events were acquired for each sample.
Lymphocytes were initially gated using forward versus side scatter,
thenCD4+ andCD8+ lymphocytes cellswere gated separately. The number
of IFN-γ expressing cells is shown as a percentage of the CD8+ or CD4+
lymphocyte population.
In vitro stimulation ofmouse splenocytes and detection of cellular responses
Three weeks after immunization, spleens were aseptically removed
and splenocytes from individual or pooled mice were stimulated in vitro
(IVS) for 1 week with syngeneic LPS blasts as APC, loaded either with the
relevant CMV-CTL epitope or CMV-peptide library (La Rosa et al., 2001,
2006). The immunological activity of the stimulated murine cultures was
determined after assessing the levels of IFN-γCD4+ or IFN-γCD8+ Tcells by
ICC staining (La Rosa et al., 2001, 2006). For CD4, CD8, and IFN-γ labeling,
APC-conjugated antibody to IFN-γ, PE-conjugated CD4, and FITC-con-
jugated CD8were used (BD, San Jose, CA). Flowcytometric acquisitionwas
performed on a FACSCanto™ (BD Immunocytometry Systems). Between
0.80 and1.0×106 eventswere acquired for each sample. FACS analysiswas
performed using FCS Express version 2 software (De Novo, Ontario,
Canada). The number of double-positive cells is expressed as a percentage
of the CD8+ T cell population.
Statistical analysis methods
Ex vivo IFN-γ production versus post-IVS with rMVA by PBMC
against pp65, IE1 and IE2 peptide libraries were compared using
Friedman's test with 2 degrees of freedom, followed by Wilcoxon's
rank-sum test for pairwise comparisons. Comparison of paired data
before and after IVS with rMVA was performed using the Student
T-test.
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